The pathogenic bacterium Staphylococcus aureus is the most common pathogen isolated in
skin-and-soft-tissue infections (SSTIs) in the United States. Most S. aureus SSTIs are caused …

The current duration of therapy in patients with Staphylococcus aureus bacteremia (SAB) is
based on differentiating complicated from uncomplicated disease. While this approach …

Background Staphylococcus aureus bloodstream infection is treated with at least 14 days of
intravenous antimicrobials. We assessed the efficacy and safety of an early switch to oral …

Staphylococcus aureus bacteremia (SAB) carries a high risk for excess morbidity and
mortality. Despite its prevalence, significant practice variation continues to permeate clinical …

Background Despite being the leading cause of mortality from bloodstream infections
worldwide, little is known about regional variation in treatment practices for Staphylococcus …

Abstract The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a
multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus …

Background Based primarily on in vitro and animal models, with little data directly
addressing patient outcomes, current guidelines recommend treating staphylococcal …

Background Staphylococcus aureus bloodstream infection (bacteraemia) is traditionally
treated with at least two weeks of IV antibiotics in adults, 3-7 days in children, and often …

Introduction The use of adjunctive antibiotics directed against exotoxin production in
Staphylococcus aureus bacteremia (SAB) is widespread, and is recommended in many …

Acute bacterial lymphadenitis is a common childhood condition, yet there remains
considerable variability in antibiotic treatment choice, particularly in settings with low …